Previous 10 | Next 10 |
The European Medicines Agency (EMA) granted orphan medicinal product designation to Applied Therapeutics' (NASDAQ:APLT) AT-007 (gavorestat) to treat Galactosemia. Galactosemia is a rare, genetic metabolic disorder which affects the body's ability to convert galactose to glucose. ...
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced designation of AT-0...
Applied Therapeutics press release (NASDAQ:APLT): Q1 GAAP EPS of -$0.88. Cash and cash equivalents and short-term investments totaled $55.7 million as of March 31, 2022, compared with $80.8 million at December 31, 2021. For further details see: Applied Therapeutics GAAP EPS of -$0.88
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
Sorbitol correlates with disease severity in patients with SORD Deficiency AT-007 treatment substantially reduced sorbitol levels in a pilot study in SORD Deficiency Sorbitol elevation results in mitochondrial dysfunction, neuronal loss, and climbing defects in a drosoph...
Applied Therapeutics Inc. (NASDAQ:APLT) traded at a new 52-week high today of $57.37. This new high was reached on above average trading volume as 6.2 million shares traded hands, while the average 30-day volume is approximately 295,000 shares. Applied Therapeutics Inc is a clinical-stag...
NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster presentatio...
Gainers: ORIC Pharmaceuticals (ORIC) +14%. Unity Biotechnology (UBX) +13%. Applied Therapeutics (APLT) +11%. Genetron (GTH) +11%. Clarus Therapeutics (CRXT) +8%. Losers: SELLAS Life Sciences SLS -39%. Pulse Biosciences (PLSE) -22%. Spero Therapeutics SPRO...
Gainers: TCR2 Therapeutics (TCRR) +16%. Precision BioSciences (DTIL) +16%. Alzamend Neuro (ALZN) +15%. BioSig Technologies (BSGM) +13%. Applied Therapeutics (APLT) +13%. Losers: ORIC Pharmaceuticals (ORIC) -29%. Applied Genetic Technologies (AGTC) -28%. NeuroSense Therapeutics (NRSN...
The following slide deck was published by Applied Therapeutics, Inc. in conjunction with this event. For further details see: Applied Therapeutics (APLT) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Applied Therapeutics Inc. Company Name:
APLT Stock Symbol:
NASDAQ Market:
Applied Therapeutics Inc. Website:
2024-07-27 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was adde...
2024-06-11 10:45:04 ET Palo Alto Networks Inc (PANW) PANW is trading UP for the last 5 days, and it at trading at $313.28 with volume of 858,188 and a one day change of $4.23 (1.37%). Palo Alto Networks Inc has a 52-week low of 201.17 and a 52-week high of $380.84. The business's 50...